Intravenous iron isomaltoside versus oral iron supplementation for treatment of iron deficiency in pregnancy: protocol for a randomised, comparative, open-label trial

Veronika Markova, Rebecka Hansen, Lars Lykke Thomsen, Anja Pinborg, Torben Moos, Charlotte Holm, Veronika Markova, Rebecka Hansen, Lars Lykke Thomsen, Anja Pinborg, Torben Moos, Charlotte Holm

Abstract

Background: Iron deficiency is common in pregnancy. If left untreated, iron deficiency can lead to iron deficiency anaemia, which is a condition related to maternal and neonatal morbidity. The prevalence of iron deficiency increases through the trimesters, which means that women with iron deficiency in the beginning of pregnancy also have a great risk of developing iron deficiency anaemia during pregnancy. Standard treatment is oral iron in individualised intensified doses based on screening values in 1st trimester. Maternal symptoms of iron deficiency and iron deficiency anaemia include fatigue, reduced physical performance, and restless legs syndrome (RLS). Severe anaemia may cause dizziness, dyspnea, palpitation, orthostatism, and syncope, and it decreases the woman's ability to cope with blood loss during delivery. The anaemia may also compromise contractility in the uterine musculature increasing the risk for prolonged labour, caesarean section, and postpartum haemorrhage. Foetal iron deficiency may cause low birthweight and adversely affect foetal and early childhood brain development with long-term deficits.

Methods: In this randomised comparative, open-label, single-centre, phase IV trial, 200 pregnant women between 14 and 21 weeks of gestation who have iron deficiency after 4 weeks of standard treatment will be randomised 1:1 to either a single 1000 mg dose of intravenously administered ferric derisomaltose/iron isomaltoside 1000 or a fixed dose of 100 mg oral ferrous fumarate containing 60 mg ascorbic acid. The primary endpoint is to prevent iron deficiency anaemia defined by a low level of haemoglobin throughout the trial. Other endpoints include other haematological indices of iron deficiency and anaemia, clinical outcomes by questionnaires, and collection of adverse events. Explorative endpoints by medical record follow-up include complications up to 7 days after delivery.

Discussion: This trial will provide evidence on how to prevent iron deficiency anaemia. The trial population represents a clinical reality where pregnant women often have sustained iron deficiency despite an increased oral iron dose. Thus, this evidence can be used to consider the optimal 2nd line of treatment in iron-deficient pregnant women.

Trial registration: European Union Drug Regulating Authorities Clinical Trials Database 2017-000776-29. Registered on 3 May 2017. ClinicalTrials.gov NCT03188445 . Registered on 15 June 2017.

Keywords: Ferric derisomaltose; Iron deficiency; Iron deficiency anaemia; Iron isomaltoside 1000; Pregnancy; Randomised controlled trial.

Figures

Fig. 1
Fig. 1
Illustration of trial flow (SF-12, Short Form 12; FACIT-fatigue, questionnaire on fatigue; AEs, adverse events; IDA, iron deficiency anaemia)
Fig. 2
Fig. 2
Schedule for enrolment, intervention, and assessment during the trial

References

    1. WHO . The global prevalence of anaemia in 2011. Geneva: World Health Organization; 2015.
    1. Greminger AR, Lee DL, Shrager P, Mayer-Proschel M. Gestational iron deficiency differentially alters the structure and function of white and gray matter brain regions of developing rats. J Nutr. 2014;144:1058–1066. doi: 10.3945/jn.113.187732.
    1. Breymann C, Honegger C, Holzgreve W, Surbek D. Diagnosis and treatment of iron-deficiency anaemia during pregnancy and postpartum. Arch Gynecol Obstet. 2010;282:577–580. doi: 10.1007/s00404-010-1532-z.
    1. van den Broek NR, Letsky EA, White SA, Shenkin A. Iron status in pregnant women: which measurements are valid? Br J Haematol. 1998;103:817–824. doi: 10.1046/j.1365-2141.1998.01035.x.
    1. WHO. World Health Organization . Iron deficiency anaemia; assessment, prevention and control; a guide for programme managers. Geneva: World Health Organization; 2001.
    1. Munoz M, Garcia-Erce JA, Remacha AF. Disorders of iron metabolism. Part II: iron deficiency and iron overload. J Clin Pathol. 2011;64:287–296. doi: 10.1136/jcp.2010.086991.
    1. Beard JL. Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr. 2001. 10.1093/jn/131.2.568S.
    1. Milman N, Byg KE, Bergholt T, Eriksen L, Hvas AM. Body iron and individual iron prophylaxis in pregnancy--should the iron dose be adjusted according to serum ferritin? Ann Hematol. 2006;85:567–573. doi: 10.1007/s00277-006-0141-1.
    1. Hernandez-Martinez C, Canals J, Aranda N, Ribot B, Escribano J, Arija V. Effects of iron deficiency on neonatal behavior at different stages of pregnancy. Early Hum Dev. 2011;87:165–169. doi: 10.1016/j.earlhumdev.2010.12.006.
    1. Cantor AG, Bougatsos C, Dana T, Blazina I, McDonagh M. Routine iron supplementation and screening for iron deficiency anemia in pregnancy: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2015;162:566–576. doi: 10.7326/M14-2932.
    1. Zimmermann MB, Hurrell RF. Nutritional iron deficiency. Lancet (London, England) 2007;370:511–520. doi: 10.1016/S0140-6736(07)61235-5.
    1. Scholl TO. Iron status during pregnancy: setting the stage for mother and infant. Am J Clin Nutr. 2005;81:1218s–1222s. doi: 10.1093/ajcn/81.5.1218.
    1. Bencaiova G, Burkhardt T, Breymann C. Anemia--prevalence and risk factors in pregnancy. Eur J Intern Med. 2012;23:529–533. doi: 10.1016/j.ejim.2012.04.008.
    1. Markova V, Norgaard A, Jorgensen KJ, Langhoff-Roos J. Treatment for women with postpartum iron deficiency anaemia. Cochrane Database Syst Rev. 2015:Cd010861. 10.1002/14651858.CD010861.pub2.
    1. Grover A, Clark-Bilodeau C, D'Ambrosio CM. Restless leg syndrome in pregnancy. Obstet Med. 2015;8:121–125. doi: 10.1177/1753495X15587452.
    1. Mayson E, Ampt AJ, Shand AW, Ford JB. Intravenous iron: barriers and facilitators to its use at nine maternity hospitals in New South Wales, Australia. Aust N Z J Obstet Gynaecol. 2016;56:162–172. doi: 10.1111/ajo.12417.
    1. Devasenapathy N, Neogi SB, Zodpey S. Is intravenous iron sucrose the treatment of choice for pregnant anemic women? J Obstet Gynaecol Res. 2013;39:619–626. doi: 10.1111/j.1447-0756.2012.02033.x.
    1. Pena-Rosas JP, De-Regil LM, Dowswell T, Viteri FE. Daily oral iron supplementation during pregnancy. Cochrane Database Syst Rev. 2012. 10.1002/14651858.CD004736.pub4.
    1. Haider BA, Olofin I, Wang M, Spiegelman D, Ezzati M, Fawzi WW. Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and meta-analysis. BMJ (Clinical research ed) 2013;346:f3443.
    1. Alwan NA, Cade JE, McArdle HJ, Greenwood DC, Hayes HE, Simpson NA. Maternal iron status in early pregnancy and birth outcomes: insights from the Baby’s Vascular health and Iron in Pregnancy study. Br J Nutr. 2015;113:1985–1992. doi: 10.1017/S0007114515001166.
    1. Goonewardene M, Shehata M, Hamad A. Anaemia in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2012;26:3–24. doi: 10.1016/j.bpobgyn.2011.10.010.
    1. Lozoff B. Iron deficiency and child development. Food Nutr Bull. 2007;28(4 Suppl):S560–S571. doi: 10.1177/15648265070284S409.
    1. Danish Society of Obstetricians and Gynaecologists . Anæmi og jernmangel under graviditet og i puerperium [Anaemia and iron deficiency in pregnancy and the puerperium] 2016.
    1. Jahn MR, Andreasen HB, Futterer S, Nawroth T, Schunemann V, Kolb U, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011. 10.1016/j.ejpb.2011.03.016.
    1. Bhandari S, Kalra PA, Berkowitz M, Belo D, Thomsen LL, Wolf M. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial. Nephrol Dial Transplant. 2020. 10.1093/ndt/gfaa011.
    1. Derman R, Roman E, Modiano MR, Achebe MM, Thomsen LL, Auerbach M. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am J Hematol. 2017;92:286–291. doi: 10.1002/ajh.24633.
    1. Auerbach M, Henry D, Derman RJ, Achebe MM, Thomsen LL, Glaspy J. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol. 2019;94:1007–1014. doi: 10.1002/ajh.25564.
    1. Wolf M, Rubin J, Achebe M, Econs MJ, Peacock M, Imel EA, et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials. JAMA. 2020;323:432–443. doi: 10.1001/jama.2019.22450.
    1. Pollock RF, Biggar P. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. Expert Rev Hematol. 2020;13:187–195. doi: 10.1080/17474086.2020.1709437.
    1. Holm C, Thomsen LL, Norgaard A, Langhoff-Roos J. Single-dose intravenous iron infusion or oral iron for treatment of fatigue after postpartum haemorrhage: a randomized controlled trial. Vox Sang. 2017;112:219–228. doi: 10.1111/vox.12477.
    1. Holm C, Thomsen LL, Norgaard A, Langhoff-Roos J. Single-dose intravenous iron infusion versus red blood cell transfusion for the treatment of severe postpartum anaemia: a randomized controlled pilot study. Vox Sang. 2017;112:122–131. doi: 10.1111/vox.12475.
    1. Reveiz L, Gyte GM, Cuervo LG, Casasbuenas A. Treatments for iron-deficiency anaemia in pregnancy. Cochrane Database Syst Rev. 2011. 10.1002/14651858.CD003094.pub3.
    1. Monofer® Summary of Product Characteristics (UK), 05/2017. . Accessed 11 June 2020.
    1. Iron C Summary of Product Characteristics (SmPC). . Accessed 11 June 2020.
    1. Teucher B, Olivares M, Cori H. Enhancers of iron absorption: ascorbic acid and other organic acids. Int J Vitam Nutr Res. 2004. 10.1024/0300-9831.74.6.403.
    1. Al RA, Unlubilgin E, Kandemir O, Yalvac S, Cakir L, Haberal A. Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial. Obstet Gynecol. 2005;106:1335–1340. doi: 10.1097/01.AOG.0000185260.82466.b4.
    1. Bayoumeu F, Subiran-Buisset C, Baka NE, Legagneur H, Monnier-Barbarino P, Laxenaire MC. Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route. Am J Obstet Gynecol. 2002;186:518–522. doi: 10.1067/mob.2002.121894.
    1. Khalafallah A, Dennis A, Bates J, Bates G, Robertson IK, Smith L, et al. A prospective randomized, controlled trial of intravenous versus oral iron for moderate iron deficiency anaemia of pregnancy. J Intern Med. 2010;268:286–295. doi: 10.1111/j.1365-2796.2010.02251.x.
    1. Singh K, Fong YF, Kuperan P. A comparison between intravenous iron polymaltose complex (Ferrum Hausmann) and oral ferrous fumarate in the treatment of iron deficiency anaemia in pregnancy. Eur J Haematol. 1998;60:119–124. doi: 10.1111/j.1600-0609.1998.tb01008.x.
    1. Breymann C, Milman N, Mezzacasa A, Bernard R, Dudenhausen J. Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP) J Perinat Med. 2017;45:443–453. doi: 10.1515/jpm-2016-0050.
    1. Tariq N, Ayub R, Khan WU, Ijaz S, Alam AY. Parenteral iron therapy in the treatment of iron deficiency anemia during pregnancy: a randomized controlled trial. J Coll Physicians Surg Pak. 2015;25:193–197.
    1. Ayub R, Tariq N, Adil MM, Iqbal M, Junaid A, Jaferry T. Efficacy and safety of total dose infusion of low molecular weight iron dextran in the treatment of iron deficiency anemia during pregnancy. J Coll Physicians Surg Pak. 2008;18:424–427.
    1. Wijemanne S, Ondo W. Restless legs syndrome: clinical features, diagnosis and a practical approach to management. Pract Neurol. 2017;17:444–452. doi: 10.1136/practneurol-2017-001762.
    1. Lee S, Guillet R, Cooper EM, Westerman M, Orlando M, Pressman E, et al. Maternal inflammation at delivery affects assessment of maternal iron status. J Nutr. 2014;144:1524–1532. doi: 10.3945/jn.114.191445.
    1. Lacroix R, Eason E, Melzack R. Nausea and vomiting during pregnancy: a prospective study of its frequency, intensity, and patterns of change. Am J Obstet Gynecol. 2000;182:931–937. doi: 10.1016/S0002-9378(00)70349-8.
    1. Chou FH, Lin LL, Cooney AT, Walker LO, Riggs MW. Psychosocial factors related to nausea, vomiting, and fatigue in early pregnancy. J Nurs Scholarsh. 2003. 10.1111/j.1547-5069.2003.00119.x.
    1. Malinowski AK, D'Souza R, Khan KS, Shehata N, Malinowski M, Daru J. Reported outcomes in perinatal iron deficiency anemia trials: a systematic review. Gynecol Obstet Investig. 2019;84:1–18. 10.1159/000495566.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere